Industry Research Reports

Home > Reports > Medical Care > Global Large Molecule Drug Substance CDMO Market Insights, Forecast to 2030

Global Large Molecule Drug Substance CDMO Market Insights, Forecast to 2030

Industry: Medical Care

Published: 2024-11-29

Pages: 147 Pages

Report ld: 3389552

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Valued at US$ 28160 million in 2024, the global Large Molecule Drug Substance CDMO market is forecast to reach US$ 59060 million by 2030, at a CAGR of 13.1% during the forecast period.

A Large Molecule Drug Substance CDMO (Contract Development and Manufacturing Organization) is a specialized company that provides outsourced services for the development and manufacturing of large molecule drugs, also known as biologics. These are complex, biologically-derived drugs, typically proteins, antibodies, or nucleic acids, which are used in the treatment of a wide variety of diseases, including cancer, autoimmune disorders, and genetic conditions.

Large Molecule Drug Substance CDMO Market Size

M= millions and B=billions

The US & Canada market for Large Molecule Drug Substance CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The China market for Large Molecule Drug Substance CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The Europe market for Large Molecule Drug Substance CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key manufacturers of Large Molecule Drug Substance CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc. In 2023, the global top five players had a share approximately % in terms of revenue.

Report Includes
This report presents an overview of global market for Large Molecule Drug Substance CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Large Molecule Drug Substance CDMO, also provides the revenue of main regions and countries. of the upcoming market potential for Large Molecule Drug Substance CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Large Molecule Drug Substance CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Large Molecule Drug Substance CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Large Molecule Drug Substance CDMO revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc.

Market Segmentation

Report Metric
Details
Report Title
Global Large Molecule Drug Substance CDMO Market Insights, Forecast to 2030
Forecasted Market Size in 2030
US$ 59060 million
CAGR(2024-2030)
13.1%
Market Size Available for Years
2019-2030
Global Large Molecule Drug Substance CDMO Companies Covered
Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals
Global Large Molecule Drug Substance CDMO Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Large Molecule Drug Substance CDMO Market, Segment by Type
Cell and Gene Therapies

Antibodies

Vaccines

Other
Global Large Molecule Drug Substance CDMO Market, Segment by Application
SMBs

Large Companies
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Large Molecule Drug Substance CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Large Molecule Drug Substance CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Large Molecule Drug Substance CDMO revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Table of Contents

 1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
        1.2.2 Cell and Gene Therapies
        1.2.3 Antibodies
        1.2.4 Vaccines
        1.2.5 Other
    1.3 Market by Application
        1.3.1 Global Large Molecule Drug Substance CDMO Market Share by Application: 2019 VS 2023 VS 2030
        1.3.2 SMBs
        1.3.3 Large Companies
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Large Molecule Drug Substance CDMO Market Perspective (2019-2030)
    2.2 Global Large Molecule Drug Substance CDMO Growth Trends by Region
        2.2.1 Global Large Molecule Drug Substance CDMO Market Size by Region: 2019 VS 2023 VS 2030
        2.2.2 Large Molecule Drug Substance CDMO Historic Market Size by Region (2019-2024)
        2.2.3 Large Molecule Drug Substance CDMO Forecasted Market Size by Region (2025-2030)
    2.3 Large Molecule Drug Substance CDMO Market Dynamics
        2.3.1 Large Molecule Drug Substance CDMO Industry Trends
        2.3.2 Large Molecule Drug Substance CDMO Market Drivers
        2.3.3 Large Molecule Drug Substance CDMO Market Challenges
        2.3.4 Large Molecule Drug Substance CDMO Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Revenue Large Molecule Drug Substance CDMO by Players
        3.1.1 Global Large Molecule Drug Substance CDMO Revenue by Players (2019-2024)
        3.1.2 Global Large Molecule Drug Substance CDMO Revenue Market Share by Players (2019-2024)
    3.2 Global Large Molecule Drug Substance CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Global Key Players of Large Molecule Drug Substance CDMO, Ranking by Revenue, 2022 VS 2023 VS 2024
    3.4 Global Large Molecule Drug Substance CDMO Market Concentration Ratio
        3.4.1 Global Large Molecule Drug Substance CDMO Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Large Molecule Drug Substance CDMO Revenue in 2023
    3.5 Global Key Players of Large Molecule Drug Substance CDMO Head office and Area Served
    3.6 Global Key Players of Large Molecule Drug Substance CDMO, Product and Application
    3.7 Global Key Players of Large Molecule Drug Substance CDMO, Date of Enter into This Industry
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Large Molecule Drug Substance CDMO Breakdown Data by Type
    4.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Type (2019-2024)
    4.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (2025-2030)

 5 Large Molecule Drug Substance CDMO Breakdown Data by Application
    5.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Application (2019-2024)
    5.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (2025-2030)

 6 North America
    6.1 North America Large Molecule Drug Substance CDMO Market Size (2019-2030)
    6.2 North America Large Molecule Drug Substance CDMO Market Size by Type
        6.2.1 North America Large Molecule Drug Substance CDMO Market Size by Type (2019-2024)
        6.2.2 North America Large Molecule Drug Substance CDMO Market Size by Type (2025-2030)
        6.2.3 North America Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
    6.3 North America Large Molecule Drug Substance CDMO Market Size by Application
        6.3.1 North America Large Molecule Drug Substance CDMO Market Size by Application (2019-2024)
        6.3.2 North America Large Molecule Drug Substance CDMO Market Size by Application (2025-2030)
        6.3.3 North America Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
    6.4 North America Large Molecule Drug Substance CDMO Market Size by Country
        6.4.1 North America Large Molecule Drug Substance CDMO Market Size by Country: 2019 VS 2023 VS 2030
        6.4.2 North America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024)
        6.4.3 North America Large Molecule Drug Substance CDMO Market Share by Country (2025-2030)
        6.4.4 United States
        6.4.5 Canada

 7 Europe
    7.1 Europe Large Molecule Drug Substance CDMO Market Size (2019-2030)
    7.2 Europe Large Molecule Drug Substance CDMO Market Size by Type
        7.2.1 Europe Large Molecule Drug Substance CDMO Market Size by Type (2019-2024)
        7.2.2 Europe Large Molecule Drug Substance CDMO Market Size by Type (2025-2030)
        7.2.3 Europe Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
    7.3 Europe Large Molecule Drug Substance CDMO Market Size by Application
        7.3.1 Europe Large Molecule Drug Substance CDMO Market Size by Application (2019-2024)
        7.3.2 Europe Large Molecule Drug Substance CDMO Market Size by Application (2025-2030)
        7.3.3 Europe Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
    7.4 Europe Large Molecule Drug Substance CDMO Market Size by Country
        7.4.1 Europe Large Molecule Drug Substance CDMO Market Size by Country: 2019 VS 2023 VS 2030
        7.4.2 Europe Large Molecule Drug Substance CDMO Market Size by Country (2019-2024)
        7.4.3 Europe Large Molecule Drug Substance CDMO Market Size by Country (2025-2030)
        7.4.4 Germany
        7.4.5 France
        7.4.6 U.K.
        7.4.7 Italy
        7.4.8 Russia
        7.4.9 Nordic Countries

 8 China
    8.1 China Large Molecule Drug Substance CDMO Market Size (2019-2030)
    8.2 China Large Molecule Drug Substance CDMO Market Size by Type
        8.2.1 China Large Molecule Drug Substance CDMO Market Size by Type (2019-2024)
        8.2.2 China Large Molecule Drug Substance CDMO Market Size by Type (2025-2030)
        8.2.3 China Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
    8.3 China Large Molecule Drug Substance CDMO Market Size by Application
        8.3.1 China Large Molecule Drug Substance CDMO Market Size by Application (2019-2024)
        8.3.2 China Large Molecule Drug Substance CDMO Market Size by Application (2025-2030)
        8.3.3 China Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)

 9 Asia (excluding China)
    9.1 Asia Large Molecule Drug Substance CDMO Market Size (2019-2030)
    9.2 Asia Large Molecule Drug Substance CDMO Market Size by Type
        9.2.1 Asia Large Molecule Drug Substance CDMO Market Size by Type (2019-2024)
        9.2.2 Asia Large Molecule Drug Substance CDMO Market Size by Type (2025-2030)
        9.2.3 Asia Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
    9.3 Asia Large Molecule Drug Substance CDMO Market Size by Application
        9.3.1 Asia Large Molecule Drug Substance CDMO Market Size by Application (2019-2024)
        9.3.2 Asia Large Molecule Drug Substance CDMO Market Size by Application (2025-2030)
        9.3.3 Asia Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
    9.4 Asia Large Molecule Drug Substance CDMO Market Size by Region
        9.4.1 Asia Large Molecule Drug Substance CDMO Market Size by Region: 2019 VS 2023 VS 2030
        9.4.2 Asia Large Molecule Drug Substance CDMO Market Size by Region (2019-2024)
        9.4.3 Asia Large Molecule Drug Substance CDMO Market Size by Region (2025-2030)
        9.4.4 Japan
        9.4.5 South Korea
        9.4.6 China Taiwan
        9.4.7 Southeast Asia
        9.4.8 India
        9.4.9 Australia

 10 Middle East, Africa, and Latin America
    10.1 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size (2019-2030)
    10.2 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Type
        10.2.1 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Type (2019-2024)
        10.2.2 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Type (2025-2030)
        10.2.3 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
    10.3 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Application
        10.3.1 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Application (2019-2024)
        10.3.2 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Application (2025-2030)
        10.3.3 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
    10.4 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Country
        10.4.1 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Country: 2019 VS 2023 VS 2030
        10.4.2 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024)
        10.4.3 Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Country (2025-2030)
        10.4.4 Brazil
        10.4.5 Mexico
        10.4.6 Turkey
        10.4.7 Saudi Arabia
        10.4.8 Israel
        10.4.9 GCC Countries

 11 Key Players Profiles
    11.1 Lonza
        11.1.1 Lonza Company Details
        11.1.2 Lonza Business Overview
        11.1.3 Lonza Large Molecule Drug Substance CDMO Introduction
        11.1.4 Lonza Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.1.5 Lonza Recent Development
    11.2 Catalent
        11.2.1 Catalent Company Details
        11.2.2 Catalent Business Overview
        11.2.3 Catalent Large Molecule Drug Substance CDMO Introduction
        11.2.4 Catalent Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.2.5 Catalent Recent Development
    11.3 Samsung Biologics
        11.3.1 Samsung Biologics Company Details
        11.3.2 Samsung Biologics Business Overview
        11.3.3 Samsung Biologics Large Molecule Drug Substance CDMO Introduction
        11.3.4 Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.3.5 Samsung Biologics Recent Development
    11.4 FUJIFILM Diosynth Biotechnologies
        11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
        11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
        11.4.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Introduction
        11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
    11.5 Boehringer Ingelheim
        11.5.1 Boehringer Ingelheim Company Details
        11.5.2 Boehringer Ingelheim Business Overview
        11.5.3 Boehringer Ingelheim Large Molecule Drug Substance CDMO Introduction
        11.5.4 Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.5.5 Boehringer Ingelheim Recent Development
    11.6 WuXi Biologics
        11.6.1 WuXi Biologics Company Details
        11.6.2 WuXi Biologics Business Overview
        11.6.3 WuXi Biologics Large Molecule Drug Substance CDMO Introduction
        11.6.4 WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.6.5 WuXi Biologics Recent Development
    11.7 Recipharm
        11.7.1 Recipharm Company Details
        11.7.2 Recipharm Business Overview
        11.7.3 Recipharm Large Molecule Drug Substance CDMO Introduction
        11.7.4 Recipharm Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.7.5 Recipharm Recent Development
    11.8 Thermo Fisher Scientific
        11.8.1 Thermo Fisher Scientific Company Details
        11.8.2 Thermo Fisher Scientific Business Overview
        11.8.3 Thermo Fisher Scientific Large Molecule Drug Substance CDMO Introduction
        11.8.4 Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.8.5 Thermo Fisher Scientific Recent Development
    11.9 AGC Biologics
        11.9.1 AGC Biologics Company Details
        11.9.2 AGC Biologics Business Overview
        11.9.3 AGC Biologics Large Molecule Drug Substance CDMO Introduction
        11.9.4 AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.9.5 AGC Biologics Recent Development
    11.10 Rentschler Biopharma
        11.10.1 Rentschler Biopharma Company Details
        11.10.2 Rentschler Biopharma Business Overview
        11.10.3 Rentschler Biopharma Large Molecule Drug Substance CDMO Introduction
        11.10.4 Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.10.5 Rentschler Biopharma Recent Development
    11.11 KBI Biopharma
        11.11.1 KBI Biopharma Company Details
        11.11.2 KBI Biopharma Business Overview
        11.11.3 KBI Biopharma Large Molecule Drug Substance CDMO Introduction
        11.11.4 KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.11.5 KBI Biopharma Recent Development
    11.12 Siegfried
        11.12.1 Siegfried Company Details
        11.12.2 Siegfried Business Overview
        11.12.3 Siegfried Large Molecule Drug Substance CDMO Introduction
        11.12.4 Siegfried Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.12.5 Siegfried Recent Development
    11.13 Aenova Group
        11.13.1 Aenova Group Company Details
        11.13.2 Aenova Group Business Overview
        11.13.3 Aenova Group Large Molecule Drug Substance CDMO Introduction
        11.13.4 Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.13.5 Aenova Group Recent Development
    11.14 GenScript
        11.14.1 GenScript Company Details
        11.14.2 GenScript Business Overview
        11.14.3 GenScript Large Molecule Drug Substance CDMO Introduction
        11.14.4 GenScript Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.14.5 GenScript Recent Development
    11.15 ProBioGen
        11.15.1 ProBioGen Company Details
        11.15.2 ProBioGen Business Overview
        11.15.3 ProBioGen Large Molecule Drug Substance CDMO Introduction
        11.15.4 ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.15.5 ProBioGen Recent Development
    11.16 Northway Biotech
        11.16.1 Northway Biotech Company Details
        11.16.2 Northway Biotech Business Overview
        11.16.3 Northway Biotech Large Molecule Drug Substance CDMO Introduction
        11.16.4 Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.16.5 Northway Biotech Recent Development
    11.17 3P Biopharmaceuticals
        11.17.1 3P Biopharmaceuticals Company Details
        11.17.2 3P Biopharmaceuticals Business Overview
        11.17.3 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Introduction
        11.17.4 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (2019-2024)
        11.17.5 3P Biopharmaceuticals Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
            13.1.1.1 Research Programs/Design
            13.1.1.2 Market Size Estimation
            13.1.1.3 Market Breakdown and Data Triangulation
        13.1.2 Data Source
            13.1.2.1 Secondary Sources
            13.1.2.2 Primary Sources
    13.2 Author Details
    13.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Cell and Gene Therapies
 Table 3. Key Players of Antibodies
 Table 4. Key Players of Vaccines
 Table 5. Key Players of Other
 Table 6. Global Large Molecule Drug Substance CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Large Molecule Drug Substance CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 8. Global Large Molecule Drug Substance CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 9. Global Large Molecule Drug Substance CDMO Market Share by Region (2019-2024)
 Table 10. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 11. Global Large Molecule Drug Substance CDMO Market Share by Region (2025-2030)
 Table 12. Large Molecule Drug Substance CDMO Market Trends
 Table 13. Large Molecule Drug Substance CDMO Market Drivers
 Table 14. Large Molecule Drug Substance CDMO Market Challenges
 Table 15. Large Molecule Drug Substance CDMO Market Restraints
 Table 16. Global Large Molecule Drug Substance CDMO Revenue by Players (2019-2024) & (US$ Million)
 Table 17. Global Large Molecule Drug Substance CDMO Market Share by Players (2019-2024)
 Table 18. Global Top Large Molecule Drug Substance CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Large Molecule Drug Substance CDMO as of 2023)
 Table 19. Global Large Molecule Drug Substance CDMO Industry Ranking 2022 VS 2023
 Table 20. Global 5 Largest Players Market Share by Large Molecule Drug Substance CDMO Revenue (CR5 and HHI) & (2019-2024)
 Table 21. Global Key Players of Large Molecule Drug Substance CDMO, Headquarters and Area Served
 Table 22. Global Key Players of Large Molecule Drug Substance CDMO, Product and Application
 Table 23. Global Key Players of Large Molecule Drug Substance CDMO, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Large Molecule Drug Substance CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 26. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2019-2024)
 Table 27. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 28. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2025-2030)
 Table 29. Global Large Molecule Drug Substance CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 30. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2019-2024)
 Table 31. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 32. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2025-2030)
 Table 33. North America Large Molecule Drug Substance CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 34. North America Large Molecule Drug Substance CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 35. North America Large Molecule Drug Substance CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 36. North America Large Molecule Drug Substance CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 37. North America Large Molecule Drug Substance CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 38. North America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 39. North America Large Molecule Drug Substance CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 40. Europe Large Molecule Drug Substance CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 41. Europe Large Molecule Drug Substance CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 42. Europe Large Molecule Drug Substance CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 43. Europe Large Molecule Drug Substance CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 44. Europe Large Molecule Drug Substance CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 45. Europe Large Molecule Drug Substance CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 46. Europe Large Molecule Drug Substance CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 47. China Large Molecule Drug Substance CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 48. China Large Molecule Drug Substance CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 49. China Large Molecule Drug Substance CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 50. China Large Molecule Drug Substance CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 51. Asia Large Molecule Drug Substance CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 52. Asia Large Molecule Drug Substance CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 53. Asia Large Molecule Drug Substance CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 54. Asia Large Molecule Drug Substance CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 55. Asia Large Molecule Drug Substance CDMO Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 56. Asia Large Molecule Drug Substance CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 57. Asia Large Molecule Drug Substance CDMO Market Size by Region (2025-2030) & (US$ Million)
 Table 58. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 59. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 60. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 61. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 62. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 63. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 64. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 65. Lonza Company Details
 Table 66. Lonza Business Overview
 Table 67. Lonza Large Molecule Drug Substance CDMO Product
 Table 68. Lonza Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 69. Lonza Recent Development
 Table 70. Catalent Company Details
 Table 71. Catalent Business Overview
 Table 72. Catalent Large Molecule Drug Substance CDMO Product
 Table 73. Catalent Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 74. Catalent Recent Development
 Table 75. Samsung Biologics Company Details
 Table 76. Samsung Biologics Business Overview
 Table 77. Samsung Biologics Large Molecule Drug Substance CDMO Product
 Table 78. Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 79. Samsung Biologics Recent Development
 Table 80. FUJIFILM Diosynth Biotechnologies Company Details
 Table 81. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 82. FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Product
 Table 83. FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 84. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 85. Boehringer Ingelheim Company Details
 Table 86. Boehringer Ingelheim Business Overview
 Table 87. Boehringer Ingelheim Large Molecule Drug Substance CDMO Product
 Table 88. Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 89. Boehringer Ingelheim Recent Development
 Table 90. WuXi Biologics Company Details
 Table 91. WuXi Biologics Business Overview
 Table 92. WuXi Biologics Large Molecule Drug Substance CDMO Product
 Table 93. WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 94. WuXi Biologics Recent Development
 Table 95. Recipharm Company Details
 Table 96. Recipharm Business Overview
 Table 97. Recipharm Large Molecule Drug Substance CDMO Product
 Table 98. Recipharm Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 99. Recipharm Recent Development
 Table 100. Thermo Fisher Scientific Company Details
 Table 101. Thermo Fisher Scientific Business Overview
 Table 102. Thermo Fisher Scientific Large Molecule Drug Substance CDMO Product
 Table 103. Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 104. Thermo Fisher Scientific Recent Development
 Table 105. AGC Biologics Company Details
 Table 106. AGC Biologics Business Overview
 Table 107. AGC Biologics Large Molecule Drug Substance CDMO Product
 Table 108. AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 109. AGC Biologics Recent Development
 Table 110. Rentschler Biopharma Company Details
 Table 111. Rentschler Biopharma Business Overview
 Table 112. Rentschler Biopharma Large Molecule Drug Substance CDMO Product
 Table 113. Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 114. Rentschler Biopharma Recent Development
 Table 115. KBI Biopharma Company Details
 Table 116. KBI Biopharma Business Overview
 Table 117. KBI Biopharma Large Molecule Drug Substance CDMO Product
 Table 118. KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 119. KBI Biopharma Recent Development
 Table 120. Siegfried Company Details
 Table 121. Siegfried Business Overview
 Table 122. Siegfried Large Molecule Drug Substance CDMO Product
 Table 123. Siegfried Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 124. Siegfried Recent Development
 Table 125. Aenova Group Company Details
 Table 126. Aenova Group Business Overview
 Table 127. Aenova Group Large Molecule Drug Substance CDMO Product
 Table 128. Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 129. Aenova Group Recent Development
 Table 130. GenScript Company Details
 Table 131. GenScript Business Overview
 Table 132. GenScript Large Molecule Drug Substance CDMO Product
 Table 133. GenScript Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 134. GenScript Recent Development
 Table 135. ProBioGen Company Details
 Table 136. ProBioGen Business Overview
 Table 137. ProBioGen Large Molecule Drug Substance CDMO Product
 Table 138. ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 139. ProBioGen Recent Development
 Table 140. Northway Biotech Company Details
 Table 141. Northway Biotech Business Overview
 Table 142. Northway Biotech Large Molecule Drug Substance CDMO Product
 Table 143. Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 144. Northway Biotech Recent Development
 Table 145. 3P Biopharmaceuticals Company Details
 Table 146. 3P Biopharmaceuticals Business Overview
 Table 147. 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Product
 Table 148. 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (2019-2024) & (US$ Million)
 Table 149. 3P Biopharmaceuticals Recent Development
 Table 150. Research Programs/Design for This Report
 Table 151. Key Data Information from Secondary Sources
 Table 152. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 2. Global Large Molecule Drug Substance CDMO Market Share by Type: 2023 VS 2030
 Figure 3. Cell and Gene Therapies Features
 Figure 4. Antibodies Features
 Figure 5. Vaccines Features
 Figure 6. Other Features
 Figure 7. Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 8. Global Large Molecule Drug Substance CDMO Market Share by Application: 2023 VS 2030
 Figure 9. SMBs Case Studies
 Figure 10. Large Companies Case Studies
 Figure 11. Large Molecule Drug Substance CDMO Report Years Considered
 Figure 12. Global Large Molecule Drug Substance CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 13. Global Large Molecule Drug Substance CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global Large Molecule Drug Substance CDMO Market Share by Region: 2023 VS 2030
 Figure 15. Global Large Molecule Drug Substance CDMO Market Share by Players in 2023
 Figure 16. Global Top Large Molecule Drug Substance CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Large Molecule Drug Substance CDMO as of 2023)
 Figure 17. The Top 10 and 5 Players Market Share by Large Molecule Drug Substance CDMO Revenue in 2023
 Figure 18. North America Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 19. North America Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
 Figure 20. North America Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
 Figure 21. North America Large Molecule Drug Substance CDMO Market Share by Country (2019-2030)
 Figure 22. United States Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 23. Canada Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Europe Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 25. Europe Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
 Figure 26. Europe Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
 Figure 27. Europe Large Molecule Drug Substance CDMO Market Share by Country (2019-2030)
 Figure 28. Germany Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. France Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. U.K. Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Italy Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Russia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 33. Nordic Countries Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. China Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. China Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
 Figure 36. China Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
 Figure 37. Asia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Asia Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
 Figure 39. Asia Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
 Figure 40. Asia Large Molecule Drug Substance CDMO Market Share by Region (2019-2030)
 Figure 41. Japan Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. South Korea Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. China Taiwan Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Southeast Asia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 45. India Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Australia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Share by Type (2019-2030)
 Figure 49. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Share by Application (2019-2030)
 Figure 50. Middle East, Africa, and Latin America Large Molecule Drug Substance CDMO Market Share by Country (2019-2030)
 Figure 51. Brazil Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 52. Mexico Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 53. Turkey Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 54. Saudi Arabia Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 55. Israel Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 56. GCC Countries Large Molecule Drug Substance CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 57. Lonza Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 58. Catalent Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 59. Samsung Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 60. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 61. Boehringer Ingelheim Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 62. WuXi Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 63. Recipharm Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 64. Thermo Fisher Scientific Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 65. AGC Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 66. Rentschler Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 67. KBI Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 68. Siegfried Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 69. Aenova Group Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 70. GenScript Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 71. ProBioGen Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 72. Northway Biotech Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 73. 3P Biopharmaceuticals Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2019-2024)
 Figure 74. Bottom-up and Top-down Approaches for This Report
 Figure 75. Data Triangulation
 Figure 76. Key Executives Interviewed

Description

Valued at US$ 28160 million in 2024, the global Large Molecule Drug Substance CDMO market is forecast to reach US$ 59060 million by 2030, at a CAGR of 13.1% during the forecast period.

A Large Molecule Drug Substance CDMO (Contract Development and Manufacturing Organization) is a specialized company that provides outsourced services for the development and manufacturing of large molecule drugs, also known as biologics. These are complex, biologically-derived drugs, typically proteins, antibodies, or nucleic acids, which are used in the treatment of a wide variety of diseases, including cancer, autoimmune disorders, and genetic conditions.

The China market for Large Molecule Drug Substance CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The Europe market for Large Molecule Drug Substance CDMO is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Market Segmentation